001     12540
005     20240711085559.0
024 7 _ |2 DOI
|a 10.1149/1.3476296
024 7 _ |2 WOS
|a WOS:000281306900040
024 7 _ |2 ISSN
|a 0013-4651
024 7 _ |2 ISSN
|a 0096-4743
024 7 _ |2 ISSN
|a 0096-4786
024 7 _ |2 ISSN
|a 1945-7111
037 _ _ |a PreJuSER-12540
041 _ _ |a eng
082 _ _ |a 540
084 _ _ |2 WoS
|a Electrochemistry
084 _ _ |2 WoS
|a Materials Science, Coatings & Films
100 1 _ |0 P:(DE-HGF)0
|a Fonseca, F.C.
|b 0
245 _ _ |a Temperature and Bias Effects on Sputtered Ceria Diffusion Barriers for Solid Oxide Fuel Cells
260 _ _ |a Pennington, NJ
|b Electrochemical Society
|c 2010
300 _ _ |a B1515 - B1519
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
440 _ 0 |0 3889
|a Journal of the Electrochemical Society
|v 157
|x 0013-4651
|y 10
500 _ _ |a F.C.F. is thankful for the Brazilian agencies FAPESP (2007/08686-8) and CNPq (306422/2007-7). Thanks also to F. Vondahlen for helping us with PVD depositions and W. Herzhof and K. Portulidou for sample supplying/cathode depositions.
520 _ _ |a This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
536 _ _ |0 G:(DE-Juel1)FUEK402
|2 G:(DE-HGF)
|a Rationelle Energieumwandlung
|c P12
|x 0
536 _ _ |0 G:(DE-Juel1)SOFC-20140602
|a SOFC - Solid Oxide Fuel Cell (SOFC-20140602)
|c SOFC-20140602
|f SOFC
|x 1
588 _ _ |a Dataset connected to Web of Science, Pubmed
650 _ 7 |2 WoSType
|a J
700 1 _ |0 P:(DE-Juel1)129580
|a Uhlenbruck, S.
|b 1
|u FZJ
700 1 _ |0 P:(DE-Juel1)VDB86736
|a Nédélec, R.
|b 2
|u FZJ
700 1 _ |0 P:(DE-Juel1)129662
|a Sebold, D.
|b 3
|u FZJ
700 1 _ |0 P:(DE-Juel1)129594
|a Buchkremer, H. P.
|b 4
|u FZJ
773 _ _ |0 PERI:(DE-600)2002179-3
|a 10.1149/1.3476296
|g Vol. 157, p. B1515 - B1519
|p B1515 - B1519
|q 157|t Journal of the Electrochemical Society
|v 157
|x 0013-4651
|y 2010
856 7 _ |u http://dx.doi.org/10.1149/1.3476296
856 4 _ |u https://juser.fz-juelich.de/record/12540/files/FZJ-12540_PV.pdf
|y Restricted
|z Published final document.
909 C O |o oai:juser.fz-juelich.de:12540
|p VDB
913 1 _ |0 G:(DE-Juel1)FUEK402
|a DE-HGF
|b Energie
|k P12
|l Rationelle Energieumwandlung
|v Rationelle Energieumwandlung
|x 0
913 2 _ |0 G:(DE-HGF)POF3-135
|1 G:(DE-HGF)POF3-130
|2 G:(DE-HGF)POF3-100
|a DE-HGF
|b Forschungsbereich Energie
|l Speicher und vernetzte Infrastrukturen
|v Fuel Cells
|x 0
914 1 _ |y 2010
915 _ _ |0 StatID:(DE-HGF)0010
|a JCR/ISI refereed
920 1 _ |0 I:(DE-Juel1)IEK-1-20101013
|g IEK
|k IEK-1
|l Werkstoffsynthese und Herstellverfahren
|x 0
970 _ _ |a VDB:(DE-Juel1)124203
980 _ _ |a VDB
980 _ _ |a ConvertedRecord
980 _ _ |a journal
980 _ _ |a I:(DE-Juel1)IEK-1-20101013
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)IMD-2-20101013


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21